Additional recurrent SCNVs
We sought additional CTCL drivers among the remaining significant focal SCNVs (Online Methods and Supplementary Tables 12 and 13). Within seven narrow GISTIC segments containing nine or fewer genes (mean of four genes), we found TNFAIP3, a nuclear factor (NF)-κB inhibitor recently implicated in CTCL 10 (deleted in 25% of CTCLs; only two genes in the GISTIC interval). We annotated the remaining SCNVs for consensus cancer drivers 17 , thereby identifying ATM (deleted in 30% of CTCLs; 5 genes in the GISTIC interval) and CTCF (deleted in 15% of CTCLs; 2 genes in the GISTIC interval); the identification of 2 known cancer drivers among the 28 genes in these 7 focal intervals was not expected by chance (P = 0.01, binomial distribution) ( Supplementary  Table 14a ).
In the remaining four intervals, we used GRAIL 18 to identify genes significantly related to other mutated genes, as has been done previously 19 . PRKCQ, encoding an enzyme in the TCR signaling pathway 20 (amplified in 30% of CTCLs; nine genes in the GISTIC interval; GRAIL P value = 6.8 × 10 −5 ), and IRF4, encoding a transcription factor required for the expansion of TCR-activated T cells 21 (amplified in 5% of CTCLs; five genes in the GISTIC interval; GRAIL P value = 0.0015), were implicated (Supplementary Table 14b ). Tables 7 and 13) .
No genes reached significance in the remaining two narrow deletions (Supplementary
Collectively, these results implicate 17 genes in CTCL (Fig. 1) . None showed significant co-occurrence or mutual exclusivity of alterations. npg
Recurrent protein-altering mutations
There were recurrent mutations in six genes, including previously unreported recurrent SSNVs in CD28 and known recurrent mutations in other cancers in RHOA [22] [23] [24] , BRAF 25 and STAT5B 26 , as well as previously described mutations in two genes previously suggested to have a role in CTCL (PLCG1 and NFKB2) 9, 11 ( Fig. 2 , Tables 1 and 2,  and Supplementary Tables 5-8) .
CD28 encodes a co-stimulatory T cell surface molecule that binds B7 ligands (CD80 and CD86) on antigen-presenting cells, promoting the production of pro-proliferative cytokines and antiapoptotic Bcl family members 27 . CD28 harbored four SSNVs (Q = 3.3 × 10 −4 ), all affecting the extracellular domain. Targeted sequencing of eight additional CTCLs identified two more SSNVs, collectively identifying three SSNVs affecting Phe51 and two SSNVs affecting Gln77, with each alteration unlikely to have occurred by chance (point-wise P value = 9 × 10 −9 and 1.3 × 10 −4 , respectively). The p.Phe51Val alteration identified was also previously reported in a single case of angioimmunoblastic T cell lymphoma (AITL) 24 . Interestingly, these amino acid positions are spatially clustered and are inferred to be involved in the binding of B7 ligands (Fig. 2a,b) .
The CD28 and CTLA-4 B7 ligand-binding domains are homologous but have opposing effects on T cell activation 28 . CTLA-4 and CD28 differ by having valine versus phenylalanine residues at homologous positions (Val69 in CTLA-4 and Phe51 in CD28), with the amino acids flanking these positions interacting with B7 ligands 27 (Fig. 2c,d) . Because CTLA-4 binds to B7 ligands with 50-to 200-fold greater affinity than CD28 (ref. 27) , we hypothesized that the CD28 SSNVs encoding p.Phe51Val and p.Phe51Ile might increase avidity for ligands.
To test this hypothesis, we used a wellcharacterized assay 29 . We expressed wild-type or mutant CD28 in 293T cells and incubated the cells with B7 fusion proteins comprising the extracellular domain of B7 fused to human Fc domains. B7 binding was detected with a fluorescently labeled antibody recognizing human Fc domain, and the extent of binding was adjusted for the level of cell surface expression of CD28. Although wild-type and mutant (Phe51Val and Gln77Pro) CD28 proteins showed no significant difference in binding to CD80-Fc (Supplementary Fig. 6 ), both mutants demonstrated >2-fold higher avidity in binding to CD86-Fc (Fig. 2e,f and Supplementary Fig. 7a,b) .
We anticipated that the increased avidity of mutant CD28 would cause increased liganddependent signaling. We expressed wild-type and Phe51Val CD28 in Jurkat T cells. Mutant CD28 again showed higher avidity for CD86-Fc (Supplementary Fig. 7c-f) . We compared the ability of wild-type and mutant CD28 to augment IL2 expression in response to stimulation with phorbol ester and ionomycin 30 in the presence of increasing concentrations of CD86-Fc. Induction of IL2 was significantly greater with mutant CD28 (Fig. 2g) .
RHOA encodes a small GTPase, recently found to be mutated in AITL 23, 24 , peripheral T cell lymphoma-not otherwise specified (PTCL-NOS) 22 and diffuse-type gastric cancer 31, 32 . A recurrent SSNV encoding p.Gly17Val has been shown to have a dominant-negative effect 22 . We found a different recurrent somatic mutation in two CTCL samples (encoding p.Asn117Ile; point-wise P = 1.1 × 10 −4 ) (Fig. 2a) . Targeted sequencing of eight more CTCLs identified an additional SSNV encoding p.Cys16Arg previously seen in PTCL [22] [23] [24] . The p.Asn117Ile, p.Cys16Arg and p.Gly17Val substitutions identified were all localized to the GTP-binding pocket in the structure of RHOA ( Supplementary  Fig. 8a) . Notably, both p.Asn117Ile 33 and p.Gly17Val [22] [23] [24] abolish the binding of GTP by RhoA, and the encoded proteins are dominant negative owing to their sequestration of guanine nucleotide exchange factors, impairing the formation of GTP-bound molecules 24, 34 .
We also found new mutations in two oncogenes previously identified in CTCL, PLCG1 (ref. 11) and NFKB2 (ref. 9). Two PLCG1 mutations (encoding p.Ser345Phe and p.Ser520Phe) that significantly increase enzymatic activity have been reported 11 . We found one instance of the p.Ser345Phe substitution and three previously unreported alterations, including the nearby p.Asp342Asn, p.Arg48Trp and p.Glu1163Lys substitutions ( Fig. 2a and Supplementary Fig. 8b ). The recurrence of a known gainof-function mutation is unlikely to be a chance event (P = 0.006, NS, nonsense (premature termination) mutation; MS, missense mutation; FS, frameshift mutation; SS, splice-site mutation. Numbers in parentheses represent the number of CTCLs with the indicated SSNVs. The Q value is the family-wise error rate for burden of SSNVs and focal SCNVs. The likelihood ratio represents the probability of the total number of somatic mutations in the listed gene occurring by chance divided by the probability for the next most likely gene in the focal SCNV interval.
a The likelihood ratio is based on the number of focal deletions and damaging SSNVs (frameshift, nonsense or splice-site mutations). b Includes two truncating mutations (one deletion and a splice-site mutation) upstream of exon 17 and three truncating deletions upstream of exon 18.
npg
A r t i c l e s binomial distribution) and, along with another tightly linked alteration, supports the relevance of PLCG1 mutations in CTCL. We identified four deletions with a breakpoint within NFKB2 and one new splice-site mutation in this gene, which regulates the non-canonical NF-κB pathway. These alterations were tightly clustered, and all were inferred to delete the autoinhibitory C terminus of NF-κB2. Similar truncations have been found in lymphomas and result in constitutive activation of the non-canonical NF-κB pathway 9 (Fig. 2a, Table 2 and Supplementary Fig. 9 ). In addition, heterozygous deletion of NFKB2 occurred in 57.5% of CTCLs (Supplementary Table 7 ). These events included 13 focal deletions with a minimum common region of only 10 genes. Full-length NF-κB2 can inhibit the canonical NF-κB pathway via its C-terminal domain, and the deletion of this domain can augment TCR-dependent activation of the canonical NF-κB pathway 35 .
Lastly, we found known gain-of-function mutations previously found in other cancers. The mutation in BRAF encoding p.Asp594Asn is a recurrent oncogenic mutation in melanoma that activates the mitogen-activated protein kinase (MAPK) pathway 25 , and the mutation in STAT5B encoding p.Asn642His is a recurrent oncogenic mutation in CD8 + large granular T cell leukemia 26 , which increases the transcription of STAT5B target genes. Dysregulated STAT5 signaling is critical for CTCL cell proliferation 36 and the immunosuppressive effects of CTCL cells on normal T cells 37 . Both BRAF and STAT5B reside within significant focal amplifications found in 10% of the CTCLs, and, when these frequencies were combined with those of arm-level amplifications, these genes were amplified in 17.5% and 62.5% of CTCLs, respectively (Fig. 1b and Supplementary Table 8 ).
Because the GISTIC intervals at 7q34 and 17q11.2 were large, we Relative IL2 transcript levels were determined by quantitative RT-PCR, using GAPDH as a control. The graph plots the means and s.e.m. of five biological replicates. Statistical significance was assessed by two-sided paired-ratio t test in e-g: *P < 0.05, **P < 0.005, ***P < 0.0005.
cannot exclude the possibility of additional target genes in these amplicons. Nonetheless, STAT5B is known to impart oncogenic effects by gene locus amplification alone 38, 39 .
Recurrently deleted genes
The seven GISTIC intervals with localizing data implicating a single gene included the truncating NFKB2 mutations. In addition, six segments that were deleted in 40-90% of CTCLs harbored putative tumor suppressors, including TP53 (SCNVs or SSNVs in 92.5% of CTCLs), which was already implicated by a significant burden of SSNVs. TP53 harbored 4 focal deletions, the minimum overlapping interval of which included TP53 and only 3 other genes, and was also deleted by 32 arm-level chromosome SCNVs. Although it is possible that the arm-level deletions impart effects via genes in addition to TP53, no other gene on 17p had a statistically significant burden of gene-localizing mutations (Q values for all other 17p genes = 1). Other known tumor suppressors included CDKN2A (mutated in 40% of CTCLs) and FAS (mutated in 42.5% of CTCLs). In addition, we found recurrent loss-offunction mutations in ARID1A (deleted or mutated in 62.5% of CTCLs), DNMT3A (42.5% of CTCLs) and ZEB1 (65% of CTCLs), none of which have previously been implicated in CTCL (Fig. 3a-d , Table 2 and Supplementary Figs. 10 and 11) . Mutations in five of these genes were frequently biallelic ( Fig. 1b and Table 2 ), whereas ARID1A had exclusively heterozygous deletions or damaging SSNVs, consistent with findings in other cancer types 40 .
ZEB1 encodes a zinc-finger transcriptional repressor. ZEB1 is a known oncogene in epithelial cancers 41 . In contrast, in CTCL as well as in adult T cell leukemia/lymphoma (ATLL) 42 , recurrent deletions implicate ZEB1 as a tumor suppressor. In CTCL, six samples harbored biallelic alterations. These included 5 homozygous deletions (with a range of 1-8 genes homozygously deleted; all including ZEB1) and a deletion in trans to a damaging SSNV (Figs. 1b and 3a,b) . Consistent with this inference, ZEB1 binds to the promoters of multiple genes implicated in T cell proliferation and differentiation. For example, decreased ZEB1 expression augments IL2 transcription 43 .
Interestingly, ZEB1-binding sites occur upstream of the transcription initiation site of GATA3, which encodes a transcription factor whose expression is sufficient for T H 2 T cell polarization 44 . GATA3 is overexpressed in TCR-stimulated CTCL cells, which are constitutively polarized toward a T H 2 phenotype in vivo 2 . We hypothesized that ZEB1 loss might contribute to GATA3 overexpression in stimulated T cells. Knockdown by small interfering RNA (siRNA) or short hairpin RNA (shRNA) of ZEB1 in stimulated Jurkat cells caused significantly increased GATA3 expression (Fig. 3e and Supplementary Fig. 12 ). (f) Gene expression is altered by deletion and amplification. The transcript levels (in FPKM) of all genes when diploid were normalized to a z score of 0 with a standard deviation of 1. Means ± s.e.m. for the transcript levels of the same genes when they were heterozygously deleted or amplified are shown. (g) z scores of putative driver genes with at least three CTCLs diploid for the indicated gene. For f and g, statistical significance was calculated using the χ 2 test of difference from the null hypothesis that the transcript levels for deleted or amplified genes were equally likely to be higher or lower than the mean transcript level when the gene was diploid. 
Changes in expression of genes within recurrent SCNVs
We evaluated changes in gene expression for genes that reside in SCNVs. Among the 11 CTCL samples with RNA-seq data, 3,752 genes were deleted a mean of 2.22 times (total of 8,317 gene deletions). We compared the RNA transcript levels (in fragments per kilobase per million mapped reads, FPKM) of each gene in haploid and diploid states. We found that 87% of genes showed haploid transcript levels lower than the diploid mean levels (7,224 of 8,317; P < 1 × 10 −300 , χ 2 test; Fig. 3f ). There were 19 deletions in 7 tumor-suppressor genes and 9 amplifications in 2 genes in this set, with RNA-seq data available for at least 3 diploid tumors at each of these loci (Fig. 3g) . The transcript levels for 18 of the 19 deleted genes were lower than the mean level for diploid CTCLs (P = 9.6 × 10 −5 , χ 2 test), with the mean FPKM 55% of the value without deletion. Similar results were observed for amplifications, with all nine amplifications resulting in expression levels above the mean (P = 0.003, χ 2 test; mean expression in amplified samples was 169% of diploid levels). Analysis of individual driver genes in at least three diploid CTCLs and three CTCLs with SCNVs demonstrated statistically significant lower transcript levels for all four deleted genes (ARID1A, P = 0.016; CTCF, P = 0.042; TNFAIP3, P = 0.012; ZEB1, P = 0.024). Similarly, all eight CTCLs with STAT5B amplification had significantly increased transcript levels of STAT5B (P = 0.012) (Supplementary Table 15 ).
High frequency of pathogenic SCNVs
The data showed a striking bias for SCNVs as drivers of CTCL. There were 12 statistically significant chromosome-arm SCNVs and 36 significant focal SCNVs; these collectively occurred 473 times in the CTCLs analyzed (mean of 7.5 focal deletions, 1.6 broad deletions, 1.0 focal amplification and 1.8 broad amplifications per CTCL; Figs. 1-3 , Supplementary Fig. 4 and Supplementary Tables 7-10 ). In contrast, there were a total of only 38 SSNVs in CTCL driver genes (1.0 per tumor; Supplementary Table 5) . Thus, 92% of driver alterations in these CTCLs were SCNVs. This distribution sharply contrasts with the bias for mutation of tumor suppressors in other malignancies. For example, TP53 was deleted or mutated in 92.5% of CTCLs with a SCNV/SSNV ratio of 5.1:1, whereas in 17 other cancers with available data the mean ratio was 0.9:1 (range of 0.08:1 to 2.0:1). Similarly, the SCNV/SSNV ratio for DNMT3A was 3.75:1 in CTCL versus 0.1:1 in acute myelogenous leukemia (AML) (Fig. 4a) .
Further, ARID1A was deleted in 23 CTCLs, with only 2 SSNVs. Similar patterns were seen for ATM, CDKN2A, FAS and ZEB1 (Fig. 3a) . Collectively, for the nine tumor suppressors identified 
TP53 DNMT3A
Ratio of deletions to SSNVs + amplifications (Fig. 1b, Table 2 and Supplementary Table 14) , somatic deletions accounted for 88% of the mutated alleles. We further compared the relative frequencies of pathogenic SCNVs and SSNVs in CTCL and 21 other cancers with publically available data from The Cancer Genome Atlas (TCGA) (Online Methods). The ratio of significant focal deletions to significant focal amplifications and SSNVs in CTCL was 4.8:1, in comparison to a mean ratio of 1:1 for 21 other cancers (range of 0:1 to 2. 7:1; Fig. 4b) . Given that 18 genes were deleted 8-23 times each, whereas no gene had more than 7 SSNVs and no other gene statistically implicated in any cancer had more than 4 SSNVs, this ratio will not be altered by sequencing larger cohorts of CTCL.
High frequency of complex structural rearrangements
The molecular events producing deletions were obscure from exome data. These events were elucidated by whole-genome sequencing of 2 CTCLs, which identified 51 precise breakpoints contributing to 39 deletion events identified by exome sequencing ( Supplementary  Figs. 13 and 14, and Supplementary Table 16 ). Of the somatic deletions identified, 39% resulted from two or more chromosomal translocations with loss of intervening genomic DNA, and 31% and 21% of deletions resulted from intrachromosomal deletions and chromosomal inversions, respectively. Strikingly, 79% of these deletions were associated with complex structural rearrangements (Supplementary Table 16 ). Using previously employed definitions of chromothripsis (evidence of more than ten copy number states on a single chromosome 45 ), we found that 65% of CTCL samples had evidence of at least one chromothripsis-like rearrangement ( Fig. 4c and Supplementary Fig. 15 ). Interestingly, these events occurred most frequently on chromosomes harboring multiple CTCL tumor suppressors, allowing concurrent focal deletion of genes not closely linked on the same chromosome. For example, chromosome 10 showed complex rearrangement in nine CTCLs (22.5%), producing deletion of ZEB1 (nine CTCLs) and FAS (four CTCLs) and deletions of the NFKB2 sequence encoding the C terminus of the protein (three CTCLs) (Fig. 4c-e) . Similarly, ARID1A (four CTCLs) and DNMT3A (five CTCLs) were frequently deleted by chromothripsis-like events on chromosomes 1 and 2, respectively (Fig. 4c) . These results are distinct from the distribution of chromothripsis events identified by the TCGA pan-cancer analysis, which reported the highest incidence of these events on chromosomes 6, 9 and 12, with few chromosome 10 events 46 .
Enrichment of RAG heptamers in CTCL breakpoints
Because of the high incidence of narrow deletions (median focal deletion size of 1.6 Mb), we considered the possibility that breakpoints might often result from endonuclease-mediated cleavage by RAG proteins (RAG1 and RAG2). The RAG proteins initiate V(D)J recombination in developing lymphocytes by cleaving relatively well-conserved heptamer and nonamer elements. Recently, the RAG proteins were implicated in recurrent deletions in ETV6-RUNX1-positive acute lymphoblastic leukemias 47 , with consensus RAG heptamers found in a 55-bp window flanking deletion breakpoints in 40% of cases 47 . Using the same algorithm (Online Methods), we found consensus RAG heptamers flanking 12.7% of the CTCL deletion breakpoints ( Supplementary  Fig. 16a,b) . This proportion was significantly higher than those seen for deletion breakpoints in epithelial cancers with available data (P < 0.05, Fisher's test) ( Fig. 4f and Supplementary Fig. 16b) .
We examined recurrent structural variants for high-scoring RAG cleavage sites, as RAG proteins have been implicated in several recurrent translocations 48 . In our whole-genome sequencing data, we found a high-scoring heptamer at both ends of the intragenic NFKB2 translocation in CTCL 17 (Fig. 4g) . We identified from the literature four additional B cell lymphomas with defined breakpoints leading to C-terminal truncation of NF-κB2 (ref. 9) . These five breakpoints all clustered within a 1-kb segment. Two harbored high-scoring heptamers (recombination signal sequence (RSS) > 8.55) within the 55-bp window flanking the breakpoint (P = 0.005, binomial distribution) (Supplementary Fig. 16c) . A third breakpoint harbored a heptamer with an RSS of 7.55; 13.6% of rearrangements at the endogenous human TCR locus had RSS scores between 7.5 and 8.55 ( Supplementary  Fig. 17) . The presence of heptamers with RSS >7.5 in three of five NFKB2 breakpoints is unlikely to have occurred by chance (P = 0.003, binomial distribution) (Supplementary Fig. 16c ).
DISCUSSION
These findings implicate somatic mutations in 17 genes in CTCL. We find frequent deletions and damaging SSNVs in chromatinmodifying genes (ARID1A (62.5%), CTCF (12.5%) and DNMT3A (42.5%)). Many genes mutated in CTCL also contribute to other T cell neoplasms, including PTCL (CD28, DNMT3A and RHOA) [22] [23] [24] 49 , T cell large granular lymphocytic leukemia (STAT5B) 26 and ATLL (ZEB1) 42 , underscoring the importance of these genes for the malignant transformation of mature T cells. Consistent with this notion, we found mutations in multiple components of the TCR signaling pathway, including CD28 and the genes for TCR-associated enzymes (PLCG1, PRKCQ and TNFAIP3) and transcription factors (NFKB2, STAT5B and ZEB1). We found mutations in genes that drive T H 2 differentiation (ZEB1), that facilitate escape from TGF-β-mediated growth suppression 42 (ZEB1) and that facilitate resistance to TNFRSFmediated apoptosis 50 
(FAS and ARID1A).
We identified an additional 23 significant focal SCNVs whose length precluded the confident identification of single gene drivers. Eight of these contained at least one consensus cancer gene (for example, RB1 (ref. 51) , deleted in 25% of CTCLs) (Supplementary Table 12) . In eight additional intervals, GRAIL analysis suggested candidate target genes (Supplementary Tables 12 and 13) , including PDCD1 (biallelically deleted in 5% of CTCLs and heterozygously deleted in 15% of CTCLs; GRAIL P value = 0.0035), CARD11 (amplified in 22.5% of CTCLs; GRAIL P value = 0.0003) and JAK2 (amplified in 12.5% of CTCLs; GRAIL P value = 3.27 × 10 −5 ). PDCD1 prevents continuous T cell proliferation in the setting of chronic TCR engagement 52 . CARD11 and JAK2 are known oncogenes in hematological malignancies [53] [54] [55] , encoding critical components of the NF-κB 56 and STAT5 (ref. 54) signaling pathways, respectively. In the two remaining narrow intervals (with three or fewer genes), GRAIL identified LATS1 (deleted in 22.5% of CTCLs; P value = 0.17) and ZNF365 (deleted in 50% of CTCLs; GRAIL P value = 0.58) as the most likely target genes (Supplementary Table 12) . Lastly, we identified 12 significant broad SCNVs, including chromosome 8q amplifications (42.5% of CTCLs; Q = 3.9 × 10 −11 ) that occur in many cancers 19 and contain the MYC oncogene 57 (Supplementary Table 10) .
The genomic architecture of CTCL is unusual in having a large contribution of focal deletions (7.5 significant focal deletions/sample ;  Figs. 3a,b and 4a,b) . The possible involvement of RAG proteins in these events is surprising given that CTCLs are thought to derive from RAG-negative mature T cells. Additional whole-genome sequencing will be necessary to further evaluate the link between RAG proteins and genome instability in CTCL.
Our findings establish CD28 as an oncogene. Recurrent p.Phe51Val and p.Gln77Pro alterations increase CD28 avidity for CD86, which enhances downstream signaling. A single instance of the p.Phe51Val npg A r t i c l e s substitution was recently reported in AITL, lending further support to the relevance of this recurrent alteration 24 . The increased avidity conferred by these alterations is similar to that resulting from amino acid substitutions in the second-generation CTLA-4-Fc fusion protein, belatacept 58 . A recent report in PTCL identified another recurrent substitution in CD28 in the intracellular domain (p.Thr195Pro) 24 . We posit that this alteration might also augment CD28 signaling.
These findings have potential therapeutic implications. Frequent mutations activating the NF-κB pathway (NFKB2 truncations and TNFAIP3 mutation) suggest the potential usefulness of NF-κB inhibitors such as bortezomib; a recent small phase II clinical trial supports this possibility 59 and suggests that the correlation of alterations in these genes with response to therapy should be evaluated. Similarly, CD28 mutations suggest therapeutic potential for inhibitors of binding such as abatacept (CTLA-4-immunoglobulin), which is used in autoimmune disease 60 . Lastly, CTCL responds to histone deacetylase inhibitors 61 , raising the question of whether the frequent mutations in chromatin-modifying genes account for this sensitivity. The genomic landscape of CTCL defined here shapes therapeutic opportunities and presents challenges for the future.
URLs. The Cancer Genome Atlas (TCGA), https://tcga-data.nci.nih. gov/tcga/dataAccessMatrix.htm; GRAIL, http://www.broad.mit.edu/ mpg/grail/.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The deidentified whole-genome sequencing, wholeexome sequencing and RNA-seq data have been deposited to the Sequence Read Archive (SRA) according to the guidelines outlined by the Yale Institutional Review Board. The accession code for this data is SRP058948. 
ONLINE METHODS
Sample selection and preparation. This study was reviewed and approved by the human subjects institutional review boards (IRBs) of the Yale School of Medicine and the Johns Hopkins University School of Medicine. Written informed consent was obtained from all living participants. We chose to perform whole-exome sequencing on leukemic CTCL from 40 patients. The patients all had stage IVA-B CTCL with a detectable abnormal population in the blood. Leukemic cells were isolated by FACS using cell surface markers that uniquely identified the neoplastic clones. If the antibody to TCRVβ was available, we isolated the CD3 + TCRVβ + CD14 − CD8 − CD19 − population. If not, we isolated CD3 + CD26 − CD14 − CD8 − CD19 − cells. We found that the mutational spectra of cells were similar regardless of the method of isolation. For the normal controls, we isolated CD14 + CD3 − CD8 − CD19 − monocytes. The median purity of the CTCL tumor cells and matched normal monocytes was 98% (Supplementary Fig. 1) . None of the patients had concomitant AML or myelodysplasia. All antibodies were from BD Biosciences. DNA was extracted from the cells using standard techniques (Qiagen).
Sequencing. For whole-exome sequencing, DNA libraries were prepared by Covaris sonication, size selected and ligated to specific barcoded adaptors (Illumina TruSeq) for multiplexed analysis. Targeted capture was performed using the NimbleGen 2.1 Exome reagent, followed by sequencing on the Illumina HiSeq system. All samples achieved >140× coverage in exon regions. Sequences were aligned to human genome Build 36 with ELAND (Illumina).
Somatic mutation calling and identification of significantly mutated genes.
The significance of differences in read distribution between tumor and monocyte sequencing data was evaluated at all covered positions, using a two-tailed Fisher's exact test. P value-ranked lists of somatic calls identified in the tumor were compared to variant calls unique to blood by the same analysis, and a P-value significance threshold was determined independently for each tumor to yield a list of high-confidence somatic calls. Somatic mutations were filtered to remove variants present in public and Yale databases, which are likely miscalled germline variants. Previous studies have demonstrated an inverse relationship between gene expression and mutation rate 13 . To define the RNA levels of genes in CTCL, we used a previously described data set 5 . We confirmed in our data set an inverse relationship between gene expression and mutation rate (R 2 = −0.90604). Significantly mutated genes were identified using the previously described convolution test (CT) approach 62 . CT calculates a summarized log statistic of joint binomial point probability, as first proposed by Getz et al. 63 . Significant recurrent missense mutations were identified as previously described 64 . For known recurrent somatic mutations implicated in CTCL or other cancers, the probability of recurrence in the CTCL set by chance was calculated from the length of the coding region, total number of known recurrent sites in the gene and total number of observed somatic mutations in the CTCL set.
Somatic copy number mutations. Somatic copy number data were generated from whole-exome sequencing data for the 40 matched samples using the coverage depth ratio and changes in B-allele frequency (BAF) of informative SNPs between each tumor and matched normal sample. To identify SCNVs, the coverage ratio was first normalized by the GC content and overall coverage depth of the exome using CONTRA 65 . Contiguous chromosomal segments with similar copy numbers were merged. The SCNVs were confirmed by ∆BAF. Segments with discordant ∆BAF and coverage depth were discarded for the analysis. We defined focal SCNVs as chromosomal segments covering half of a chromosome arm and broad SCNVs as those covering more than half of a chromosome arm. Homozygous deletions were defined as SCNVs with a mean log 2 relative ratio (LRR) <-2.0. For the sake of clarity, SCNVs at the TCR gene loci, which are deleted in all mature CD4 + T cells, were manually excluded from the analysis. To identify the events that occur more often than expected by chance, we used GISTIC 2.0 (ref. 14) . To identify genes in recurrent focal lesions, we used the following settings: arbitrated peel-off, confidence interval = 90% and FDR < 0.25. To identify candidate target genes, we first identified genes with significant gene-localizing mutations (see below). We then identified consensus cancer genes identified to be significantly mutated by TCGA across multiple tissue types 17 . When possible, we used tumor suppressors as the target gene within recurrent deletions and oncogenes as the target gene within recurrent amplifications. For the remaining intervals, we performed GRAIL analysis (see below) to identify the target gene. The lone exception was TNFAIP3, which was recently implicated in leukemic CTCL 10 .
Identification of specific genes in significant SCNV intervals. For each significant SCNV (focal and broad), the probability of the observed number of focal SCNVs and protein-altering SSNVs occurring by chance in each gene was determined from the binomial distribution, and Q values were calculated using Bonferroni correction for 20,025 protein-coding genes to produce a family-wise error rate. The likelihood ratio favoring the most likely gene over the next most likely gene in each interval was calculated from the reciprocal of the ratio of their P values. Focal deletions were attributed to a gene if the deletion included at least one coding exon of the gene. Amplifications were analyzed similarly except that the entire coding region had to be encompassed by the SCNV to be included. Genes with a likelihood ratio >1,000:1 were considered significant. GRAIL analysis. We used the GRAIL algorithm 18 (see URLs) with default settings to identify target genes in focal SCNVs that are functionally related to driver genes identified by gene-localizing mutations. All PubMed abstracts were queried until October 2014. The genes identified by gene-localizing mutations were ARID1A, BRAF, CDKN2A, CD28, DNMT3A, FAS, NFKB2, PLCG1, RHOA, STAT5B, TP53 and ZEB1. The significant focal amplifications and deletions were queried together.
Whole-genome sequencing. CTCL DNA for two cases was prepared for short-insert (500-bp) library construction flow cell preparation and cluster formation using the Illumina no-PCR protocol 66 . We performed 150-bp paired-end sequencing on an Illumina HiSeq 2000. Sequenced reads were aligned to the human genome (NCBI Build 37) using the Burrows-Wheeler aligner (BWA) with default settings 67 .
Somatic copy number mutations from whole-genome sequencing. SCNVs were identified as segments with altered coverage depth and allelic imbalance using Pathwork-R 68 . As described previously, the genome is segmented into 50-kb bins, coverage is normalized for GC content and segments of similar copy number are joined by circular binary segmentation. Simultaneously, single-nucleotide variants are extracted using SAMtools, and discovered variants are filtered using a list of known SNPs (dbSNP). Segments are assigned a copy number on the basis of coverage depth and allelic imbalance (Supplementary Fig. 2 ). Breakpoint identification. We identified anomalous paired-end reads supporting a structural variant using Breakdancer as previously described 69 . To resolve the breakpoint at base-pair resolution, we queried the fastq files for the soft-and hard-clipped reads at each breakpoint. Complex genomic rearrangements were defined as requiring more than the minimum number of breakpoints for the structural variant, i.e., two breakpoints for a deletion or inversion and four breakpoints for a translocation event. These included unbalanced translocations, i.e., requiring the involvement of three or more chromosomes, such as chromoplexy (multiple contiguous translocations between two or more chromosomes) or chromothripsis (deletions or inversions without loss of all of the genomic regions between the breakpoints; intervening DNA is inserted into another genomic region).
RNA sequencing. mRNA from 11 samples was isolated, extracted and subject to sequencing on an Illumina HiSeq 2000 as previously described 70 . There were a median of 87 million unique reads per sample. The RNA was aligned and quantified by FPKM using the Tuxedo suite as previously described 71 . Transcript levels (in FPKM) were assessed in CTCLs with and without SCNVs. P values were calculated using the χ 2 test of the null hypothesis that a gene in an SCNV has an equal probability of being expressed at higher or lower levels than the mean of the diploid value. One-sided P values are reported for deletions showing lower expression and amplifications showing higher expression. For analysis of expression of individual genes, npg expression of genes with RNA-seq data from at least three diploid and three SCNV tumors was analyzed by Mann-Whitney test.
TCGA analysis. We downloaded the data matrices from TCGA on 15 February 2014. On 5 February 2015, the data for each cancer in the initial analysis were updated. For analysis of individual genes, we counted the number of SSNVs and the number of deletions (focal and broad) for each gene. For the global analysis, we did the following. We summed the SSNVs that occurred in genes determined by MutSig to have an FDR or Q value <0.25. Loci for significant focal deletions and focal amplifications were determined by GISTIC with an FDR or Q value <0.25. We then summed the number of times each significant deletion GISTIC confidence interval was focally deleted. Similar analysis was performed for the amplifications. These sums were used to calculate the ratio of significant focal deletions to the sum of SSNVs and significant focal amplifications.
Identification of RAG heptamers. As described previously, we used FIMO to identify high-scoring heptamers 72 . We used a similarly sized window at the breakpoint, assuming resection of −5 to 50 bp from the heptamer to the breakpoint 47 . We evaluated the incidence of high-scoring heptamers in CTCL versus other cancers using the one-sided Fisher's test. For the NFKB2 analysis, we generated a sliding window of 55 bp within 2 kb of the NFKB2 breakpoints. We calculated the prevalence of 55-bp windows harboring a heptamer with an RSS of 8.55 or greater (0.08) and the prevalence of 55-bp windows harboring a heptamer with an RSS of 7.5 or greater (0.16). The statistical enrichment of high-scoring heptamers in 55-bp windows at NFKB2 breakpoints was calculated by the binomial distribution. For the human TCR analysis, we downloaded the reference RSS sequences from the human TCR gene loci from RSSsite 73 . RSS scores were calculated for these sequences using FIMO from the MEME suite 72 .
Structural modeling. Structural modeling of CD28 and its interactions with CD80 and CD86 was performed using PDB structures 1YJD (CD28) 27 and 1I85 (CTLA-4-CD86) 20 . CD28 coordinates were extracted from PDB 1YJD and superimposed using secondary structure alignment with CTLA-4 using COOT software 74 and energy minimized within UCSF Chimera (Resource for Biocomputing, Visualization and Informatics, University of California, San Francisco). Figures were prepared using UCSF Chimera.
